EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis

Cancer Science

Volumn 102, Issue 2, 2011, Pages 351-360

  Heeg, Steffen ^a,b   Hirt, Nina ^a   Queisser, Angela ^a,b   Schmieg, Hannah ^a,b   Thaler, Michaela ^a   Kunert, Heike ^a,b   Quante, Michael ^a   Goessel, Gitta ^a   Von Werder, Alexander ^a   Harder, Jan ^a,b   Beijersbergen, Roderick ^c   Blum, Hubert E ^a,b   Nakagawa, Hiroshi ^d   Opitz, Oliver G ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; ENZYME ACTIVATION; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; KERATINOCYTE; MOLECULAR PATHOLOGY; MOUTH CANCER; MOUTH MUCOSA; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MOUTH NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 79952087345     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01796.x     Document Type: Article

References (55)

1. Goessel G, Quante M, Hahn WC et al. Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci USA 2005; 102: 15599-604.
2. Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001; 108: 725-32.
3. Stewart SA, Hahn WC, O'Connor BF et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99: 12606-11.
4. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-8.
5. Lundberg AS, Randell SH, Stewart SA et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002; 21: 4577-86.
6. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003; 17: 88-100.
7. Choi J, Southworth LK, Sarin KY et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet 2008; 4: e10.
8. Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 2005; 24: 1320-7.
9. Artandi SE, Alson S, Tietze MK et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 2002; 99: 8191-6.
10. Quante M, Heeg S, von Werder A et al. Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis. Carcinogenesis 2005; 26: 1879-89.
11. Hahn WC, Stewart SA, Brooks MW et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-70.
12. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 2002; 21: 688-97.
13. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999; 59: 826-30.
14. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002; 21: 541-52.
15. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001; 269: 1-12.
16. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-9.
17. Chen J, Zhao S, Nakada K et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162: 1283-91.
18. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 2000; 275: 30934-42.
19. Li B, Cheung PY, Wang X et al. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 2007; 28: 2313-20.
20. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-90.
21. Kimura A, Ohmichi M, Kawagoe J et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004; 23: 4505-15.
22. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24: 1167-76.
23. Yatabe N, Kyo S, Maida Y et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004; 23: 3708-15.
24. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006; 25: 61-9.
25. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 2004; 24: 6076-83.
26. Bellon M, Nicot C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood 2008; 112: 2946-55.
27. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 2001; 493: 21-5.
28. Yang K, Zheng D, Deng X, Bai L, Xu Y, Cong YS. Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway. J Cell Biochem 2008; 105: 1194-201.
29. Rezvani HR, Dedieu S, North S et al. Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007; 282: 16413-22.
30. Mylonis I, Chachami G, Samiotaki M et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006; 281: 33095-106.
31. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 2005; 65: 3257-63.
32. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
33. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
34. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-52.
35. Elenbaas B, Spirio L, Koerner F et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15: 50-65.
36. Liu J, Yang G, Thompson-Lanza JA et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64: 1655-63.
37. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res 2001; 61: 3556-60.
38. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-603.
39. Zhao JJ, Gjoerup OV, Subramanian RR et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003; 3: 483-95.
40. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997; 272: 16729-32.
41. Akiyama M, Hideshima T, Hayashi T et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002; 62: 3876-82.
42. Yu CC, Lo SC, Wang TC. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells. Biochem J 2001; 355: 459-64.
43. Chang JT, Lu YC, Chen YJ et al. hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer 2006; 94: 870-8.
44. Liu K, Hodes RJ, Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 2001; 166: 4826-30.
45. Kyo S, Kanaya T, Ishikawa H, Ueno H, Inoue M. Telomerase activity in gynecological tumors. Clin Cancer Res 1996; 2: 2023-8.
46. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558-61.
47. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med 2001; 31: 847-55.
48. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 2005; 17: 1-9.
49. Child ES, Mann DJ. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 2006; 5: 1313-9.
50. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-9.
51. Asada M, Yamada T, Ichijo H et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18: 1223-34.
52. Xia W, Chen JS, Zhou X et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004; 10: 3815-24.
53. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001; 21: 5644-57.
54. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002; 277: 11352-61.
55. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339-45.